Inspire Medical SystemsINSP
Recorded

Inspire Medical Systems 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration51 minParticipants19

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon. My name is Dilem, and I will be your conference operator today. At this time, I would like to welcome everyone to the Inspire Medical Systems Third Quarter 2026 Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. I will now hand the call over to your first speaker, Louisa Smith from Gilmartin Group. You may begin the conference.

Tim HerbertChairman and CEO

Thank you, Dilem. Joining me on today's call are Tim Herbert, Chairman and Chief Executive Officer, and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the three months ended September 30, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of federal securities laws. All forward-looking statements, including without limitation, those relating to our operations, financial results, financial condition, investments in our business, financial and operational outlook for 2026 and future periods, and changes in market access and different aspects of coding or reimbursement, are based upon our current estimates and various assumptions. Forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements.

Tim HerbertChairman and CEO

For discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission, including our periodic reports on Form 10-K and 10-Q, as well as the Form 10-Q, which we filed this afternoon with the SEC for the quarter ended September 30, 2026. Inspire disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, November 2, 2026. With that, I will turn the call over to Tim.

Matt OsbergCFO

Go ahead. Thanks, Louisa. Thank you to everyone for joining today's call.

Matt OsbergCFO

To start, the focus of our employees and the physician and care teams we work with is delivering the best possible outcomes for patients. OSA, a largely untreated condition, and the more we learn about it, the clearer it becomes that its impact goes beyond sleep to a patient's underlying health. Our Inspire therapy is the market leader for hypoglossal nerve stimulation treatment for OSA, and we believe that better treatment leads to better sleep, which leads to better health. This belief shapes how we approach everything we do. For the third quarter, we were pleased to deliver revenue and adjusted operating income slightly ahead of our expectations, with another strong quarter of operating cash flow and a 3% sequential revenue increase.

Matt OsbergCFO

Coding has been a central topic this year, so I'll provide an update using the same near, mid, and long-term lens we shared in August. In the near term, we continue to work closely with physicians and staff on the new billing procedures. As with any abrupt workflow change, it took time for implanting sites to get comfortable with the new rules. Over the last several months, centers have gained experience with a stable, temporary billing framework. We expect centers to continue to use this framework and grow increasingly comfortable with it throughout 2027. For the midterm, back in July of this year, CMS announced the proposed OPPS rules for 2027 hospital and ASC reimbursement, but the final OPPS rule has not yet been released.

Matt OsbergCFO

The proposed rule in July showed a significant increase, although we will confirm only once the final rule is published, which we expect to be later this week. Longer term, we were pleased by the recently approved Category I CPT code for single-lead hypoglossal nerve stimulation, which covers the Inspire V device. This dedicated Category I code is set to take effect on January 1, 2028, and stands to meaningfully simplify coding and reimbursement, thereby expanding access to Inspire therapy. With the code now approved, the focus shifts to the RUC valuation and reimbursement review process. This process has been started, and physicians have been completing the RUC surveys sent out by the ENT Society. We will continue to provide updates as these activities progress toward the code's January 1, 2028 effective date.

Matt OsbergCFO

Overall, we are in a much more favorable position with coding than we were just last quarter and are increasingly confident in our path forward. We are very pleased with the work our internal team and external partners did to help prepare us to have the best chance of securing a new code and achieving a favorable outcome. I also want to highlight some of the exciting work we are doing in expanding our clinical evidence and how this strengthens our underlying value proposition. Recent studies and publications include the full results of the Inspire V trial, a secondary analysis of the STAR trial data, a TriNetX meta-analysis, and the PREDICTOR study, all of which further support Inspire therapy's efficacy and positive impact on patient outcomes.

Matt OsbergCFO

We remain excited about the strong data from the early clinical assessments of Inspire V, which we updated at the most recent ENT conferences, the American Academy of Otolaryngology and the International Surgical Sleep Society. The accelerometer-based sensing showed improved inspiratory overlap compared to Inspire IV, meaning more of the stimulation is synchronized with the patient's inspiration. Median AHI also fell markedly at six months, showing a substantial reduction in the burden of disease. As we build that evidence, we are looking beyond AHI as a quantitative measure of OSA severity, which is simply the number of breathing events per hour, to hypoxic burden, which measures the overall systemic impact of oxygen deprivation during sleep.

Matt OsbergCFO

With further analysis of our STAR trial data, we saw a significant reduction in hypoxic burden with Inspire therapy, and even further independent studies are now looking at how that connects to cardiovascular risk and underlying health. In the TriNetX analysis, Inspire therapy was associated with significantly lower odds of stroke, heart attack, and atrial fibrillation compared to a CPAP. What it tells us is that sleep apnea is not just a sleep problem, it is an overall health problem, and that is foundational for expanding access to care beyond ENTs and sleep doctors. We are early in that work, but we currently have field team resources targeting a cardiology-based call point to expand our market reach into adjacent specialties. We look forward to sharing more as this initiative develops. With the improved coding landscape, our primary commercial focus is shifting to improving patient flow.

Matt OsbergCFO

By optimizing our organizational structure and consolidating production through Project Horizon, we created approximately $30 million of annualized growth investment capacity. We are directing those funds to our highest impact revenue initiatives, which center on expanding access to care, improving patient education and engagement, and helping patients navigate their treatment journey. We began making these investments in the third quarter and will further invest in the fourth quarter in order to build momentum for 2027. One example is adding field roles in approximately 40 high-potential growth markets to improve patient flow, increase capacity, and support continued growth. Further, we have made incremental marketing investments to create more targeted patient outreach and education, and are continuing to enhance our prior authorization process, navigator program, and Inspire Connect platform to improve our patient pathway. Inspire remains the market leader in lasting OSA treatment, and we look to expand our market share.

Matt OsbergCFO

Adoption of Inspire V has been strong, and it now makes up the vast majority of our procedures. The market remains under-penetrated, with a large and growing population of patients who could benefit from our therapy. As we look to 2027, we are encouraged by how the pieces are coming together. The current coding framework is stable, with a new code coming in 2028, the evidence for Inspire V continues to build, and Horizon is directing resources to patient flow optimization initiatives. Improvements like these take time to move through the system, but we feel confident that much of the disruption is behind us. The coding and reimbursement path is clear, and we are moving forward with conviction to drive a return to growth. With that, I'll turn the call over to Matt.

Jonathan BlockAnalyst

Thank you, Tim, and good afternoon, everyone. I'll begin with a review of our third quarter results before providing an update on our 2026 outlook. Third quarter revenue was $206.7 million, down 7.9% from prior year and up 3% sequentially from the second quarter. Our revenue achievement was driven by stronger-than-expected results in the U.S., which offset international revenue underperformance. Gross margin was 86%, up 20 basis points from prior year. The increase was primarily due to a higher sales mix of Inspire V, which carries a higher gross margin than Inspire IV. Operating expenses were $206.6 million, an increase of $23.5 million over prior year. The increase was primarily due to $24.1 million of restructuring charges related to Project Horizon, $7 million of legal settlement expense, and higher legal fees, partially offset by lower marketing and stock-based compensation expenses.

Jonathan BlockAnalyst

Adjusted operating expense was $176 million compared with $181.8 million last year. Our operating loss was $28.7 million compared with operating income of $9.6 million last year. Adjusted operating income was $1.9 million compared with $10.9 million last year. The effective tax rate was 2.5% compared with 26.7% last year, primarily driven by the current period pre-tax loss and discrete tax charges related to restructuring. Our adjusted effective tax rate was 27% compared with 26.5% last year. We had a diluted loss per share of $0.84, and our adjusted diluted earnings per share was $0.14. Our adjusted EBITDA margin declined 130 basis points to 18.3%, primarily due to the decrease in revenue.

Jonathan BlockAnalyst

Turning to cash flow and the balance sheet, operating cash flow for the quarter was $46.4 million, with year-to-date operating cash flow of $82.5 million compared to $64.5 million in the year-to-date period prior year. Our balance sheet remains strong with no debt and cash and investments of $453.1 million as of the end of the quarter. Our strong balance sheet and free cash flow conversion gives us the opportunity to continue to invest in growth initiatives. Turning to our outlook for the full year, we are narrowing our revenue outlook to a range of $850 million-$860 million. In addition, we now expect adjusted operating margin of 4.5%-5.5%, diluted loss per share of $0.36-$0.10, and adjusted diluted earnings per share of $1.20-$1.40.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day